Shionogi

This study compared two medications, edaravone and sodium ozagrel, for treating acute ischemic stroke. Researchers wanted to see which drug helped more people recover with little or no disability three months after treatment. The study included 401 adults who started treatment wi…

This study tests a new biologic drug called redasemtide in 680 adults who have had an acute ischemic stroke. Participants receive either the drug or a placebo within 25 hours of their stroke. The goal is to see if redasemtide improves recovery and reduces disability at 90 days. T…

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier edaravone studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the med…

This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease compared to a placebo over 24 weeks. The main measure was a scale of daily function. The trial did not show …

This study tested a drug called MCI-186 in 25 people with advanced ALS (severity grade III) to see if it could slow the disease. Participants received either the drug or a placebo daily through an IV for 24 weeks. The main goal was to measure changes in daily function and safety,…

This Phase 3 trial tested the drug edaravone (MCI-186) in 206 people with ALS. Participants received daily intravenous infusions for 14 days, followed by a rest period, repeated over 24 weeks. The goal was to see if edaravone could slow the decline in physical function compared t…

This study tested the drug edaravone (MCI-186) in 181 people with ALS, a progressive nerve disease. Participants received either edaravone or a placebo through IV infusions over 24 weeks. The goal was to see if edaravone could slow the decline in physical function. Results sugges…

This study looked at the long-term safety of an oral form of edaravone in 185 adults with ALS. Participants took the medication for 24 to 48 weeks, and researchers tracked any side effects. The goal was to see if taking the drug by mouth is safe over time for people with this pro…

This study tested the long-term safety of an oral form of edaravone in 124 people with ALS over 96 weeks. Participants took the drug in cycles of 10 days on and 14 days off. The main goal was to see how safe and tolerable the treatment was over time.

This study tested a drug called Edaravone (MCI-186) in 36 people who had an acute ischemic stroke. The goal was to check the drug's safety and how the body processes it. Participants received either Edaravone or a placebo through an IV over 72 hours. The trial was completed, but …

This study looked at how the antibiotic cefiderocol works in hospitalized infants under 3 months old with suspected or confirmed gram-negative bacterial infections. Researchers measured drug levels in the blood and checked for side effects in 30 babies. The goal was to find the r…

This study tested the safety and how the body processes the antibiotic cefiderocol in hospitalized children aged 3 months to 18 years with serious bacterial infections. The goal was to see if the drug is safe and how it works in the body. 53 children participated, and the study i…

This completed Phase 2 study tested an oral antiviral drug called S-892216 in 282 adults with mild-to-moderate COVID-19. Participants took either the drug or a placebo tablet for a short time. The main goal was to see if the drug could lower the amount of virus in the nose and th…

This large Phase 3 study tested an antiviral pill called S-217622 in over 2,000 adults with mild to moderate COVID-19 who were not hospitalized. Participants started the drug within 3 days of symptoms. The main goal was to see if the drug shortens symptom duration compared to a p…

This phase 3 trial tested a new COVID-19 vaccine called S-268019-b in nearly 10,000 adults. Participants received either the vaccine or a placebo to see if it could prevent COVID-19. The study looked at how many people got sick after vaccination and checked for safety and immune …

This early-phase trial tested an oral form of edaravone in 74 healthy adult males to see how safe it is and how the body processes it. Participants received single or multiple doses of the drug or a placebo. The study is complete and focused on gathering basic safety and drug-lev…

This early-stage study looked at how the body handles a single dose of oral edaravone in 6 Japanese ALS patients who have a feeding tube (gastrostomy). The goal was to measure drug levels in the blood and urine, not to test if it works. No treatment benefit was evaluated.

This study looked at how eating different types of meals affects the way the body absorbs oral edaravone, a medication used for ALS. Sixteen healthy Japanese adults took the drug under five different dietary conditions, including fasting. The goal was to understand how food chang…

This completed Phase 1 study looked at how the drug MCI-186 (Edaravone) is processed in the body of people with severe liver impairment compared to healthy individuals. Twelve participants received a single intravenous dose. The goal was to measure drug levels and safety, not to …

This completed Phase 1 study looked at how an oral form of edaravone interacts with three other drugs (rosuvastatin, sildenafil, and furosemide) in healthy adult men. It also compared how Japanese and Caucasian men process edaravone. The goal was to gather safety and drug-level d…

This study looked at how the drug edaravone enters the body when given as a liquid by mouth or through a nasogastric tube (a thin tube that goes through the nose to the stomach). It involved 36 healthy Japanese adults aged 20 to 45. The main goal was to measure drug levels in the…

This study tested whether an oral suspension of edaravone works as well as the intravenous (IV) form in 42 healthy Japanese adults. Participants received a single dose of each version, and researchers measured drug levels in the blood to compare them. The goal was to see if the o…

This early-stage study looked at how a single dose of oral edaravone moves through the bodies of 9 Japanese adults with ALS. The main goal was to measure drug levels in the blood and urine, not to test if it helps symptoms. Researchers also tracked any side effects. The study is …

This study tested whether MCI-186, an experimental drug, changes the heart's electrical activity (QT interval) in 27 healthy adult men. Participants received a low dose, a high dose, and a placebo on separate days. The goal was to see if the drug could cause dangerous heart rhyth…

This study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to those with healthy livers. Twenty-two participants received a single dose of the drug. The goal was to see if liver problems affect how the drug …

This study looked at how the drug MCI-186 is handled by the body in people with mild or moderate kidney impairment compared to those with normal kidneys. Thirty adults received a single dose of the drug, and researchers measured its levels in the blood. The goal was to understand…

This study looks at how the body handles a new drug called S-892216 in people with mild, moderate, or severe kidney problems, including those on dialysis, compared to people with healthy kidneys. About 40 adults will take a single dose of the drug, and researchers will measure it…

This study follows about 74 adults with ALS who have already decided to take the drug Edaravone (Radicava). Researchers collect blood and urine samples over 24 weeks to measure various biomarkers—molecules that might show how the drug affects oxidative stress, inflammation, and n…

This study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects.…

This study looked at how the drug BPN14770 moves through the body in people with severe kidney problems compared to healthy people. Researchers measured drug levels in the blood and checked for side effects. The goal was to understand if kidney function affects how the drug is pr…

This early-phase trial tested the safety and processing of a new drug called S-740792 in 99 healthy adults. Participants received single or multiple doses of the drug as a liquid or tablet, and some received a placebo. The goal was to gather safety data and understand how the bod…